Ivax, BMS Suit Up In Taxol Legal Battle

August 2000
Chemical Market Reporter;08/21/2000, Vol. 258 Issue 8, p20
Trade Publication
Reports on the legal battle between Ivax Corporation and Bristol-Myers Squibb (BMS) over a generic version of Bristol-Myers' anti-cancer drug paclitaxel. Lawsuit filed by American BioScience Inc. against BMS; Details on American BioScience's motion for a preliminary injunction; Requirements when a patent has been listed in the United States Food and Drug Administration's Orange Book.


Related Articles

  • States Sue Bristol-Myers Over Cancer Drug Patents. Mullin, Rick // Chemical Week;6/12/2002, Vol. 164 Issue 24, p13 

    Reports on the lawsuit filed by several U.S. states against Bristol-Myers Squibb on the alleged delayed access for generic versions of its paclitaxel anti-cancer drug, Taxol as of June 2002. Arguments of the plaintiffs regarding the case; Reason for the decline in the sales of the drug in 2001;...

  • Generics Watch.  // Drug Store News;4/23/2001, Vol. 23 Issue 6, p22 

    Presents news briefs related to generic drugs in the United States as of April 23, 2001. Approval for marketing the BuSpar anti-anxiety drug by Bristol-Myers Squibb; Status of the negotiation between Barr Laboratories and its employees; Approval for marketing fluvoxamine maleate by Ivax.

  • Ivax gains recommendation in Europe for injectable paclitaxel anticancer drug.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p18 

    Reports on the European Medicines Evaluation Agency's recommendation of the extension of the marketing authorization for Ivax Corp.'s proprietary injectable Paclitaxel to include the treatment of metastatic breast cancer and metastatic ovarian cancer. Identification of Paclitaxel as the active...

  • Change Comes to Paclitaxel After Ivax/BMS Patent. Jarvis, Lisa // Chemical Market Reporter;10/16/2000, Vol. 258 Issue 16, p5 

    Reports that the market for the active pharmaceutical ingredient (API) is ripe for change after Ivax's launching of its generic version of Bristol-Myer Squibb's (BMS) Taxol. North American companies that will produce paclitaxel API; Factor that will affect the future growth of API; Partnership...

  • Twenty-Nine States Joint Antitrust Suit Against Bristol-Myers Squibb.  // Chemical Market Reporter;6/10/2002, Vol. 261 Issue 23, p2 

    Reports on the states that join the antitrust lawsuits against Bristol-Myers Squibb Co. Allegations against the company; Response of the company on the lawsuits.

  • Bristol-Myers Squibb loses Paclitaxel in UK.  // Chemical Market Reporter;08/31/98, Vol. 254 Issue 9, p12 

    Reports that the Patents Court in Great Britain has ruled in favor of both NaPro BioTherapeutics and Ivax Corp. in the patent claims filed against them by Bristol-Myers Squibb (BMS) regarding its Taxol drug. Difference of patent laws in the United States and Britain; BMS's disappointment about...

  • Ivax, BMS Square Off Again in Taxol Battle.  // Chemical Market Reporter;10/09/2000, Vol. 258 Issue 15, p15 

    Unveils the lawsuit filed by Ivax Corp. against Bristol-Myers Squibb (BMS) Co. and American BioScience Inc. over anti-competitive practices concerning Bristol-Myers' Taxol. Background information of the lawsuit.

  • Patent Politics. Sellers, L.J. // Pharmaceutical Executive;Oct2000, Vol. 20 Issue 10, p178 

    Comments on the growing confusion generated by the long legal battle over the patent of the chemical compound paclitaxel. Details on the infringement lawsuit filed by Bristol-Myers Squibb against Ivax; Information on an investigation launched by the Federal Trade Commission; Effect of the case...

  • Names for hi-jacking.  // Nature;2/2/1995, Vol. 373 Issue 6513, p370 

    Criticizes the use of taxol as a trademark by Bristol-Myers Squibb. Generis use of taxol; Meaning of taxol; Parallel hypothetical example of the use of the word `rock.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics